

TO THE EDITOR:

Letemovir prophylaxis in T-cell-depleted transplants: breakthrough and rebound infections in the postmarketing setting

Maria A. V. Marzolini,^{1,2} Varun Mehra,³ Kirsty J. Thomson,² Eleni Tholouli,⁴ Adrian J. C. Bloor,⁵ Anne Parker,⁶ Richard Lovell,⁷ Kim Orchard,⁸ Amy Publicover,⁹ Emma Nicholson,¹⁰ John A. Snowden,¹¹ Jennifer Byrne,¹² Anjum Khan,¹³ Maria H. Gilleece,¹³ Gerardo Errico,¹² Sara Lozano,¹⁰ Erin Hurst,⁹ Nick Duncan,⁷ Jennifer Pirrie,⁶ Philip Crea,⁴ Ben Carpenter,² Antonio Pagliuca,³ and Karl S. Peggs^{1,2}

¹Department of Haematology, UCL Cancer Institute, University College London, London, United Kingdom; ²Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom; ³Department of Haematology, Kings College Hospital, London, United Kingdom; ⁴Department of Haematology, Manchester Royal Infirmary, Manchester, United Kingdom; ⁵Department of Haematology, The Christie NHS Foundation Trust, Manchester, United Kingdom; ⁶Department of Haematology, Queen Elizabeth University Hospital, Glasgow, United Kingdom; ⁷Department of Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom; ⁸Department of Haematology, University Hospital Southampton, Southampton, United Kingdom; ⁹Department of Haematology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom; ¹⁰Department of Haematology, The Royal Marsden NHS Foundation Trust, London, United Kingdom; ¹¹Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; ¹²Department of Haematology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; and ¹³Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

We read with interest the recent article by Zamora et al describing that letemovir prophylaxis following allogeneic hematopoietic stem cell transplantation (allo-HSCT) may be associated with delayed reconstitution of cytomegalovirus (CMV)-specific T-cell immunity.¹ They hypothesize that this may be due to decreased exposure to CMV antigen. CMV infection is a cause of significant morbidity and mortality following allo-HSCT where an absolute and functional deficiency of CMV-reactive T lymphocytes can lead to the development of CMV disease.² In the pivotal phase 3 randomized clinical trial by Marty et al,³ letemovir prophylaxis given for 14 weeks following transplantation was shown to reduce the risk of clinically significant CMV infection (as defined as CMV disease or CMV viremia leading to preemptive therapy) by week 24 when compared with placebo. This led to UK National Health Service approval of the use of letemovir therapy in July 2019 as prophylaxis against CMV for the first 100 days posttransplant in CMV-seropositive allo-HSCT recipients. Although many patients in the United Kingdom receive alemtuzumab as graft-versus-host disease (GVHD) prophylaxis, only 12 patients (3.2%) in the letemovir group and 11 patients (5.7%) in the placebo group received alemtuzumab in the phase 3 clinical trial.³ In view of these small numbers, it remains unclear whether letemovir prophylaxis is effective at reducing the risk of clinically significant CMV infection in this group and whether that benefit remains once the letemovir therapy is ceased. Alemtuzumab-containing regimens are associated with both delayed CMV-specific immune reconstitution and relatively high CMV reactivation rates.^{4,5} It is therefore possible that these patients would be at particularly high risk of CMV infection following cessation of letemovir at day 100, particularly if decreased CMV antigen exposure results in further delayed CMV-specific immune reconstitution as hypothesized by Zamora et al.

In an attempt to address these issues, we performed a United Kingdom-based multicenter retrospective study of allogeneic HSCT recipients who received alemtuzumab as GVHD prophylaxis and letemovir for the first 100 days posttransplant. Twelve transplant centers contributed data on patients transplanted between July 2019 and August 2020. All transplant recipients were CMV seropositive with a requirement for at least 50 days of follow-up or until death if this was earlier. We used a historical comparator cohort of 234 consecutive CMV-seropositive recipients who received alemtuzumab-based T-cell-depleted allo-HSCT at our institution between the dates of January 2006 and February 2017 and did not receive letemovir prophylaxis. All patients had consented to collection of baseline data regarding the collected parameters for registry reporting. Statistical analyses were performed using NCSS 2020, and a *P* value <.05 was considered statistically significant. Cumulative incidences were calculated for

Submitted 28 June 2021; accepted 26 August 2021; prepublished online on *Blood Advances* First Edition 6 October 2021; final version published online 9 November 2021. DOI 10.1182/bloodadvances.2021005637.

Method for sharing data will be by e-mails to the corresponding author: m.marzolini@ucl.ac.uk.

© 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Table 1. Patient characteristics

	Letemovir group	Comparator group (no letemovir)
No. of patients	110	234
Median follow-up (d)	131 (3-311)	688 (21-4158)
Median age (y)	59 (15-73)	49 (19-68)
Sex		
Female	46	96
Male	64	138
CMV status		
Pos/Pos	81	193
Pos/Neg	29	41
Diagnosis		
ALL	9	24
AML/MDS	66	90
Lymphoma	15	108
CLL/PLL	2	7
Aplastic anemia	8	0
MPD/myelofibrosis	0	3
CML/CMML	8	1
Immunodeficiency syndrome	2	1
Donor		
Sibling	25	104
MUD	63	81
MMUD	22	49
Conditioning regimen		
Myeloablative	10	42
Reduced intensity	100	192
Maximum GVHD grade		
0 to 1	79	170
2	20	44
3 to 4	7	19
Unknown	4	1

ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder; MMUD, mismatched unrelated donor; MUD, matched unrelated donor; Neg, Negative; PLL, prolymphocytic leukemia; Pos, positive.

CMV detection and clinically significant CMV infection rates, with death without infection or clinically significant CMV infection, respectively, being the competing risks.

Patient characteristics are shown in Table 1. The majority (102/110, 92.7%) received letemovir at a dose of 240 mg once daily because of concomitant ciclosporin therapy. Compared with the comparator group, there was a significant decrease in the cumulative incidence of detection of a quantifiable CMV viral load by week 40 (51.5% [39.8% to 66.6%] vs 90.3% [86.6% to 94.2%]; P value <.0001; Figure 1A). The temporal kinetic of detection in the letemovir group mirrored that in the registration study, with a cumulative incidence of 13.2% (8.1% to 21.6%) at week 14 and 44.7% (34.3% to 58.3%) at week 24. The cumulative incidence of clinically significant CMV infection was 6.8%

(3.3% to 14.0%) at week 14 and 33.0% (23.3% to 46.7%) at week 24 (Figure 1B) compared with 81.6% (76.8% to 86.7%) and 83.8% (79.2% to 88.6%), respectively, in the comparator cohort (P value <.0001), with no statistically significant difference according to donor type (Figure 1C). By comparison, the incidence proportion was 7.7% at week 14 and 17.5% at week 24 in the registration study (with a Kaplan-Meier event rate of 18.9% [14.4% to 23.5%] at week 24). It is notable that although patients receiving alemtuzumab were considered “low risk” in the registration study, their outcomes more closely approximated those of the predefined “high-risk” cohort in terms of the increased incidence between week 14 and week 24, which was noted to relate closely to GVHD and glucocorticoid use in that cohort. Relatively few patients receiving alemtuzumab develop higher grades of GVHD. An exploratory analysis of development of clinically significant CMV infection after week 14 according to GVHD status (Figure 1D) illustrates that the main driver of the late increase is within the larger cohort with grade 0 to 1 GVHD and more likely associated with delayed immune reconstitution rather than enhanced immune suppression. Numbers in the grade 2 to 4 GVHD group limit definitive interpretation with no statistically significant difference between the curves, although it remains probable that this group does particularly poorly because of the combination of both delayed immune reconstitution and enhanced immune suppression.

Despite the relatively high incidence of late CMV events in the alemtuzumab cohort, the high levels of viremia and need for preemptive therapy without letemovir prophylaxis means that the potential therapeutic benefit and cost-effectiveness of letemovir is, however, perhaps even greater in the setting of transplants incorporating alemtuzumab. The treatment difference (letemovir-placebo) in terms of clinically significant CMV infection through week 24 was estimated at –23.5% in the registration study, but likely approaches double that in the setting of alemtuzumab-based transplants (–50.8% in our analysis). Even considering that clinically significant CMV events continued to occur after week 24 in our study, reaching a level of 39.9% by week 32, the treatment difference likely exceeds 40%. Thus, despite any additional impact letemovir may have to that of alemtuzumab-mediated T-cell depletion on slowing immune reconstitution, overall clinical benefit appears to be maintained in this group. Our data raise the question of how much additional benefit would be gained by prolonging letemovir prophylaxis in these patients. The current extension study (MK-8228-040, #NCT03930615) evaluating prolongation of prophylaxis to day 200 following allo-HSCT includes patients receiving alemtuzumab and will help to address this issue. Whether letemovir significantly delays immune reconstitution still further as indicated by the observation of Zamora et al, resulting in temporal displacement of a significant ongoing risk to later time points when patient follow-up is generally less frequent, will be an important factor in determining its optimal deployment. The evaluation of T-cell reconstitution and CMV-specific immunity parameters should be incorporated into future prospective studies as they will be critical for a deeper understanding of the issues raised and potential refinement of therapeutic strategies. We await the results of prospective clinical trials investigating this issue with interest.




Figure 1. (A) Cumulative incidence of detection of quantifiable CMV according to use of letermovir as prophylaxis. (B) Cumulative incidence of clinically significant CMV infection. (C) Cumulative incidence of preemptive CMV therapy in patients who received letermovir by donor type. (D) Cumulative incidence of clinically significant CMV infection in patients receiving letermovir with at least 14 weeks follow-up according to GVHD severity. UD, unrelated donor.

Acknowledgment: The authors thank Shu Wong for her contribution to the data collection.

Contribution: M.A.V.M. and K.S.P. designed and performed the research, analyzed the data, and wrote the paper; V.M., K.J.T., E.T., A.J.C.B., A.P., R.L., K.O., A.P., E.N., J.A.S., J.B., A.K., M.H.G., G.E., S.L., E.H., N.D., J.P., P.C., B.C., and A.P. performed the research, supplied the data, and reviewed the paper.

Conflict-of-interest disclosure: V.M. received research grants from MSD/Gilead and speakership from MSD, Gilead, Pfizer, Novartis, Jazz, Incyte. E.T. declares advisory boards for Celgene, Gilead/Kite, Jazz, Novartis, Pfizer and MSD, speaker fees for Gilead/Kite, Janssen, Jazz, Novartis, and Pfizer and consultancy for educational materials for Gilead/Kite. A.P. declares advisory board for MSD. R.L. received educational grants and speaker fees for MSD, Chugai Pharma, Astellas, Gilead, and Sanofi. E.N. declares advisory boards for Kite/Gilead, Novartis, BMS/Celgene, and Pfizer and conference support for Kite/Gilead, Novartis, and speaker fees for Kite/Gilead. J.A.S. declares honoraria for educational events supported by Jazz, Mallinckrodt, Gilead, Janssen, and Actelion, advisory board participation for Medac, and IDMC membership for a Kiadis Pharma supported clinical trial, none of which are directly related to this study.

E.H. received honoraria from MSD. K.S.P. received speaker fees from Merck. The remaining authors declare no competing financial interests.

ORCID profiles: M.A.V.M., 0000-0002-8928-9386; V.M., 0000-0001-6572-0971; A.J.C.B., 0000-0003-4550-220X; A.P., 0000-0002-4905-6860; K.O., 0000-0003-2276-3925; E.N., 0000-0002-6439-0795; J.A.S., 0000-0001-6819-3476; A.K., 0000-0001-6432-6999; N.D., 0000-0002-1191-8170; B.C., 0000-0002-7914-0799.

Correspondence: Maria A. V. Marzolini, Department of Haematology, UCL Cancer Institute, University College London, London, United Kingdom e-mail: m.marzolini@ucl.ac.uk.

References

- Zamora D, Duke ER, Xie H, et al. Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation. *Blood*. 2021;138(1):34-43.
- Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with

cytomegalovirus infection and disease. *Blood*. 1991;78(5):1373-1380.

3. Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. *N Engl J Med*. 2017;377(25):2433-2444.
4. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. *Blood*. 2002;99(12):4357-4363.
5. Juliusson G, Theorin N, Karlsson K, Frödin U, Malm C. Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival. *Bone Marrow Transplant*. 2006;37(5):503-510.